A Phase I Study of Panitumumab in Children with Solid Tumors

Full Title
A Phase I Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children with Solid Tumors

Panitumumab is a drug approved for treating patients with advanced colorectal cancer. It is a monoclonal antibody that works by binding to certain proteins on cancer cells called antigens, and attacking the cancer cells. Panitumumab is now being studied in patients with other types of cancer.

The purpose of this phase I clinical trial is to find the highest dose of panitumumab that can be given safely to children with solid tumors that have returned or persisted despite prior treatment.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have a solid tumor that has returned or persisted despite prior treatment.
  • Patients’ tumors must express the epidermal growth factor receptor (EGFR), the target of panitumumab. Patients with brain stem glioma may participate even if their tumors do not express EGFR.
  • At least 2 weeks must have passed since the completion of previous treatment, and patients must have recovered from any side effects.
  • Patients must be at least one year old and under age 18.

For more information and to inquire about eligibility for this study, please contact Dr. Paul Meyers at 212-639-5952.